Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Exenatide is a synthetic analog of exendin-4, a peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). Its molecular formula is C139H213N37O39S, and it carries the CAS Registry Number 141758-61-0. This medication belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which play a pivotal role in glucose homeostasis by mimicking the action of endogenous incretin hormones.
The primary clinical application of Exenatide is the management of type 2 diabetes mellitus in adults who have not achieved adequate glycemic control through diet, exercise, and other antidiabetic agents. It functions by stimulating insulin secretion in a glucose-dependent manner, meaning it increases insulin release only when blood sugar levels are elevated, thereby minimizing the risk of hypoglycemia. Additionally, Exenatide suppresses inappropriate glucagon secretion, slows gastric emptying, and promotes satiety, which often leads to modest weight loss in patients. These mechanisms collectively contribute to improved hemoglobin A1c levels and better overall metabolic control.
Available in immediate-release formulations for twice-daily subcutaneous injection or as an extended-release formulation administered once weekly, Exenatide offers flexibility in treatment regimens. The extended-release version provides sustained plasma concentrations over seven days, enhancing patient adherence compared to the daily dosing schedule. While generally well-tolerated, common side effects include nausea, vomiting, diarrhea, and headache, particularly during the initial phase of therapy. Serious but rare adverse events may involve pancreatitis or renal impairment, necessitating careful monitoring in susceptible individuals.
Beyond its established use in diabetes, ongoing research explores potential benefits of GLP-1 agonists for cardiovascular protection and obesity management. However, Exenatide remains a cornerstone therapy for specific populations requiring potent glycemic control with the added advantage of weight neutrality or reduction. As a recombinant protein drug, it is produced using recombinant DNA technology, ensuring high purity and consistency. Clinicians must consider individual patient profiles, including renal function and comorbidities, before initiating treatment. Overall, Exenatide represents a significant advancement in the pharmacological management of type 2 diabetes, offering a unique mechanism of action that addresses multiple pathophysiological defects associated with the disease while supporting healthy lifestyle changes.